Compare Huntington Ingalls Industries Inc (HII) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs BIO-TECHNE Corp — how do they compare? Huntington Ingalls Industries Inc trades at $328 (market cap $13.04B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Huntington Ingalls Industries Inc is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| HII | TECH | |
|---|---|---|
Market Cap | $13.04B | $11.24B |
Sector | Technology | Health |
52-Week High | $453.73 | $72.29 |
52-Week Low | $265.40 | $43.31 |
Enterprise Value | $15.96B | $11.32B |
Dividend Yield | 1.67% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $324.48, up 0.85% on the day, with a bullish technical signal driven by moving averages and recent contract wins. The company reported strong Q2 2026 results, beating EPS estimates with $5.27 versus $3.79 expected, and revenue growth of 10.9%. Key developments include a $900 million robotics partnership and new submarine contracts, supporting a positive outlook.
The stock offers upside to the consensus price target of $359.67, with 44% of analysts rating it Buy. Risks include execution challenges in shipbuilding and political headwinds. Fundamentals are solid with a P/E of 19.7 and ROE of 12.97%, but overbought RSI levels near 85.92 suggest near-term caution.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
